Skip to main content
![Creative Commons 'BY' version 4.0 license]()
Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
Main Content
For improved accessibility of PDF content, download the file to your device.
If you recently published or updated this item, please wait up to 30 minutes for the PDF to appear here.